ES2040339T3 - Procedimiento para preparar un granulo farmaceutico. - Google Patents

Procedimiento para preparar un granulo farmaceutico.

Info

Publication number
ES2040339T3
ES2040339T3 ES198888304007T ES88304007T ES2040339T3 ES 2040339 T3 ES2040339 T3 ES 2040339T3 ES 198888304007 T ES198888304007 T ES 198888304007T ES 88304007 T ES88304007 T ES 88304007T ES 2040339 T3 ES2040339 T3 ES 2040339T3
Authority
ES
Spain
Prior art keywords
preparing
procedure
pharmaceutical granule
cimetidine
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888304007T
Other languages
English (en)
Inventor
Kevin Edward Pearmain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878710966A external-priority patent/GB8710966D0/en
Priority claimed from GB878710965A external-priority patent/GB8710965D0/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Application granted granted Critical
Publication of ES2040339T3 publication Critical patent/ES2040339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L INVENCION PROPORCIONA UN PREPARADO FARMACEUTICO QUE CONTIENE CIMETIDINA DE 2-10% EN PESO EN RELACION A LA CIMETIDINA, DE UN COPOLIMERO DE METACRILATO DE DIMETILAMINOETILO Y ESTERES DE ACIDO METACRILICO NEUTROS. EL PREPARADO TIENE BUENAS CARACTERISTICAS DE PALATABILIDAD Y DE DISOLUCION.
ES198888304007T 1987-05-08 1988-05-04 Procedimiento para preparar un granulo farmaceutico. Expired - Lifetime ES2040339T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878710966A GB8710966D0 (en) 1987-05-08 1987-05-08 Pharmaceutical compositions
GB878710965A GB8710965D0 (en) 1987-05-08 1987-05-08 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2040339T3 true ES2040339T3 (es) 1993-10-16

Family

ID=26292225

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888304007T Expired - Lifetime ES2040339T3 (es) 1987-05-08 1988-05-04 Procedimiento para preparar un granulo farmaceutico.

Country Status (12)

Country Link
US (1) US5188839A (es)
EP (1) EP0290229B1 (es)
JP (1) JP2721219B2 (es)
KR (1) KR960011236B1 (es)
AU (1) AU602582B2 (es)
DE (1) DE3863963D1 (es)
ES (1) ES2040339T3 (es)
GB (1) GB2204489B (es)
GR (1) GR3002410T3 (es)
IE (1) IE61692B1 (es)
PT (1) PT87423B (es)
WO (1) WO1988008703A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
GB8710965D0 (en) * 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
DE68903605T2 (de) * 1988-05-04 1993-04-01 Smith Kline French Lab Kautablette.
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
NL8902338A (nl) * 1988-09-20 1990-04-17 Glaxo Group Ltd Farmaceutische preparaten.
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
JP2948317B2 (ja) * 1991-05-28 1999-09-13 マクニール―ピーピーシー・インコーポレーテツド 噛める薬物投与用組成物
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1993024109A1 (en) * 1992-06-04 1993-12-09 Smithkline Beecham Corporation Palatable pharmaceutical compositions
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
SE9600071D0 (sv) † 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
JP3707798B2 (ja) * 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 口内薬剤輸送系
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP3797387B2 (ja) * 1996-06-14 2006-07-19 協和醗酵工業株式会社 口腔内速崩壊錠
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
JP2001501224A (ja) * 1996-10-04 2001-01-30 メルク エンド カンパニー インコーポレーテッド 胸焼けを予防及び治療するための方法及び組成物
FR2766089B1 (fr) † 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
WO2000028988A1 (en) * 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
FR2794979B1 (fr) * 1999-06-21 2001-07-27 Patrick Veret Une nouvelle formulation de comprime composee de lactose, sorbitol, stearate de magnesium
DE60128215T2 (de) 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
WO2003075829A2 (en) * 2002-03-08 2003-09-18 M/S. Ind-Swift Limited Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ITMI20041255A1 (it) * 2004-06-22 2004-09-22 Univ Degli Studi Milano Sistemi microparticellari per somministrazione orale di sostanze biologicamente attive
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1983827A4 (en) 2006-02-01 2013-07-10 Stuart L Weg USE OF ANTIFUNGAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL CONDITIONS
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
JPS5513239A (en) * 1978-07-14 1980-01-30 Fujisawa Pharmaceut Co Ltd Fine particulate drug composition
JPS5567375A (en) * 1978-11-17 1980-05-21 Harunobu Miura Automatic washer
JPS56164122A (en) * 1980-05-21 1981-12-17 Fujimoto Seiyaku Kk Drug composition comprising cimetidine as main agent
JPS58201725A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd 褐変化防止組成物
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
GB8710965D0 (en) * 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions

Also Published As

Publication number Publication date
JP2721219B2 (ja) 1998-03-04
AU1714088A (en) 1988-12-06
GB2204489A (en) 1988-11-16
EP0290229B1 (en) 1991-07-31
DE3863963D1 (de) 1991-09-05
KR960011236B1 (ko) 1996-08-21
GB2204489B (en) 1990-11-14
AU602582B2 (en) 1990-10-18
PT87423A (pt) 1989-05-31
IE881368L (en) 1988-11-08
EP0290229A1 (en) 1988-11-09
GB8810477D0 (en) 1988-06-08
WO1988008703A1 (en) 1988-11-17
US5188839A (en) 1993-02-23
GR3002410T3 (en) 1992-12-30
JPH01503385A (ja) 1989-11-16
PT87423B (pt) 1992-09-30
KR890701101A (ko) 1989-12-19
IE61692B1 (en) 1994-11-16

Similar Documents

Publication Publication Date Title
ES2040339T3 (es) Procedimiento para preparar un granulo farmaceutico.
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
ES2032450T3 (es) Un procedimiento para preparar acetaminofen secado por pulverizacion.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.
ES8407049A1 (es) Un procedimiento para la preparacion de compuestos biciclicos.
ES2084944T3 (es) Amidas terapeuticas.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2108255T3 (es) Sistema de disolvente destinado para ser incluido en capsulas.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
BR9914606A (pt) Uso de fumaratos de dialquila
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2040290T3 (es) Resinas cambiadoras de iones cargadas con derivados del acido quinoloncarboxilico, su preparacion y aplicacion.
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
MX9307974A (es) Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso.
IT8847794A0 (it) Derivati dell'acido furanuronico, loro preparazione e loro impiego come medicamenti
ECSP941120A (es) Derivados de 1,5 benzodiazepina
IT1255968B (it) Composizioni farmaceutiche contenenti acido ursodesossicolico
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
IT1260155B (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
ES2088053T3 (es) Medicamento y empleo del mismo para el tratamiento de estados de excitacion y disfunciones nerviosas.
ES2066902T3 (es) Soluciones estables de analogos de rebecamicina y su preparacion.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 290229

Country of ref document: ES